GSK Q1 Net Income $2.34B, Revenue $10.28B and Reaffirms 2026 Guidance
GSK’s Q1 net income was $2.34 billion ($1.15 PS; $1.24 adj EPS), topping the $1.16 estimate, with $10.28 billion in revenue. It reported Q1 pretax profit £2.14 billion, core operating profit £2.65 billion up 10% CER and EPS 46.5 pence up 9% CER, reaffirming 2026 guidance of 3–5% turnover and 7–9% profit and EPS growth.
1. Strong Q1 Financial Performance
GSK reported Q1 net income of $2.34 billion, or $1.15 per share, rising to $1.24 on an adjusted basis, surpassing the $1.16 consensus. Revenue reached $10.28 billion versus $10.19 billion forecast. In sterling, pretax profit was £2.14 billion, core operating profit £2.65 billion (up 10% CER) and EPS 46.5 pence (up 9% CER).
2. Affirmed 2026 Outlook
The company reaffirmed its full-year 2026 outlook at constant exchange rates, targeting turnover growth of 3–5% and core operating profit and EPS increases of 7–9%, reflecting confidence in Specialty Medicines momentum and stable performance in Vaccines and General Medicines.